CD80 protein variant and CD80 fusion protein
Patent Information
- Application Number
- CN202380029687.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-02
- Filing Date
- 2023-03-31
- Publication Date
- 2024-11-12
AI Technical Summary
Existing monoclonal antibodies or dual antibodies targeting CTLA4 and PD-L1 may lead to insufficient costimulation of T cells in the tumor microenvironment, resulting in low patient response rates and increased drug resistance. Targeting CD80 ligands is important in cancer and autoimmune diseases. is attractive but has limited effectiveness.
Develop a CD80 protein variant or CD80 fusion protein that can bind to PD-L1, CTLA-4 and CD28, activate T lymphocytes, and inhibit the growth and proliferation of tumors or tumor cells. The CD80 protein variant or fusion protein enhances its binding activity and stability through specific amino acid mutations, including mutations in the extracellular domain or IgV domain, to enhance the affinity with PD-L1, CTLA-4 and CD28.
Significantly enhances the binding ability of CD80 protein variants or fusion proteins to PD-L1, CTLA-4 and CD28, activates T lymphocytes, significantly inhibits tumor growth, and improves the effect of anti-tumor treatment.
Smart Images

Figure 00000040_0000 
Figure 00000040_0001 
Figure 00000040_0002
Abstract
Description
CD80 protein variants and CD80 fusion proteins Technical Field
[0001] The present application relates to the field of biomedicine, and specifically to a CD80 protein variant and a fusion protein comprising the CD80 variant. Background Art
[0002] CD80, also known as B7, B7.1, or BB1, belongs to the immunoglobulin superfamily and is primarily expressed on activated B lymphocytes, activated T lymphocytes, and macrophages. CD80 receptors include CD28, CD152 (CTLA4), and PD-L1. The cis-interaction between PD-L1 and CD80 inhibits the functions of PD-1 and CTLA-4, respectively. The binding of CD28 to CD80 generates a co-stimulatory signal, enhancing T cell activation, function, and survival in response to cognate antigens. Through these mechanisms, CD80 maintains the balance between T cell activation and inhibition, exerting its attack on tumor cells.
[0003] Currently, monoclonal or bispecific antibodies targeting CTLA4 and PD-L1 have been developed to address these mechanisms. However, the lack of sufficient T cell co-stimulation in the tumor microenvironment may result in low patient response rates and drug resistance. Given the important role of CD80 ligand in immune regulation, targeting CD80 ligand has always been an attractive strategy in cancer and autoimmunity.
[0004] Summary of the Invention
[0005] The present application provides a fusion protein comprising CD80, which can bind to PD-L1, CTLA-4, and CD28 to activate the activity of T lymphocytes and inhibit the growth and / or proliferation of tumors or tumor cells. The present application also relates to a nucleic acid encoding the fusion protein, a vector comprising the fusion protein, a cell comprising the nucleic acid or the vector, a method for preparing the fusion protein, and applications of the fusion protein.
[0006] In one aspect, the present application provides a CD80 protein variant, comprising a functionally active fragment of a CD80 protein or a variant thereof, wherein the variant has a mutation in one or more amino acid positions compared to the corresponding functionally active fragment of wild-type CD80, and the variant has one or more of the following characteristics:
[0007] a) Binding to PD-L1;
[0008] b) binds to CTLA-4;
[0009] c) binds to CD28;
[0010] d) activation of T lymphocyte activity; and
[0011] e) inhibiting the growth and / or proliferation of tumors or tumor cells.
[0012] In certain embodiments, the PD-L1 is human PD-L1.
[0013] In certain embodiments, the CTLA-4 is human CTLA-4.
[0014] In certain embodiments, the CD28 is human CD28.
[0015] In certain embodiments, the functionally active fragment of the CD80 protein comprises the extracellular domain (ECD) of the CD80 protein or a fragment thereof.
[0016] In certain embodiments, the fragment of the extracellular domain of the CD80 protein comprises the IgV domain of the CD80 protein.
[0017] In certain embodiments, the CD80 protein variant comprises an amino acid mutation at one or more amino acid residues selected from the group consisting of N55, N64, N152, N173, N177, N192, and N198, compared to the corresponding wild-type CD80 protein extracellular domain or a fragment thereof.
[0018] In certain embodiments, the CD80 protein variant comprises a mutation at any one of the following amino acid positions:
[0019] 1) N64;
[0020] 2) N55 and N64;
[0021] 3) N55, N64 and N152;
[0022] 4) N55, N64 and N192;
[0023] 5) N55, N64 and N198;
[0024] 6) N55, N64, N152 and N198;
[0025] 7) N55, N64, N152 and N192;
[0026] 8) N55, N64, N152, N173, N177 and N198;
[0027] 9) N55, N64, N152, N173, and N198; and
[0028] 10) N55, N64, N152, N177 and N198.
[0029] In certain embodiments, the CD80 protein variant comprises an amino acid mutation at one or more amino acid residues selected from the group consisting of N55A / Q, N64A, N152A, N173Q, N177A, N192A, and N198A / Q, compared to a functionally active fragment of a corresponding wild-type CD80 protein.
[0030] In certain embodiments, the CD80 protein variant comprises any one of the following amino acid mutations:
[0031] 1)N64A;
[0032] 2) N55A and N64A;
[0033] 3) N55A, N64A, and N152A;
[0034] 4) N55A, N64A, and N192A;
[0035] 5) N55A, N64A, and N198A;
[0036] 6) N55A, N64A, N152A, and N198A;
[0037] 7) N55A, N64A, N152A, and N192A;
[0038] 8) N55Q, N64A, N152A and N198Q;
[0039] 9) N55Q, N64A, N152A, N173Q, N177A, and N198Q;
[0040] 10) N55Q, N64A, N152A, N173Q, and N198Q; and
[0041] 11) N55Q, N64A, N152A, N177A and N198Q.
[0042] In certain embodiments, the CD80 protein variant comprises at least one first type of amino acid mutation, and the first type of amino acid mutation can maintain or enhance the stability of the CD80 protein variant.
[0043] In certain embodiments, the CD80 protein variant comprises a first class amino acid mutation at one or more of the following amino acid positions: N55, N64, N152, N192, and N198.
[0044] In certain embodiments, the CD80 protein variant comprises a first type of amino acid mutation at any one of the following amino acid positions:
[0045] 1) N64;
[0046] 2) N55 and N64;
[0047] 3) N55, N64 and N152;
[0048] 4) N55, N64 and N192;
[0049] 5) N55, N64 and N198;
[0050] 6) N55, N64, N152, and N198; and
[0051] 7)N55, N64, N152 and N192.
[0052] In certain embodiments, the CD80 protein variant comprises one or more of the following first class amino acid mutations: N55A / Q, N64A, N152A, N192A, and N198A / Q.
[0053] In certain embodiments, the CD80 protein variant comprises any one group of first amino acid mutations selected from the following groups:
[0054] 1)N64A;
[0055] 2) N55A and N64A;
[0056] 3) N55A, N64A, and N152A;
[0057] 4) N55A, N64A, and N192A;
[0058] 5) N55A, N64A, and N198A;
[0059] 6) N55A, N64A, N152A, and N198A;
[0060] 7) N55A, N64A, N152A, and N192A; and
[0061] 8)N55Q, N64A, N152A and N198Q.
[0062] In certain embodiments, the CD80 protein variant comprises at least one second type of amino acid mutation, and the second type of amino acid mutation can maintain the binding activity of the CD80 protein variant.
[0063] In certain embodiments, the CD80 protein variant comprises a second type of amino acid mutation at one or more of the following amino acid positions: N152; N192 and N198.
[0064] In certain embodiments, the CD80 protein variant comprises one or more of the following second-class amino acid mutations: N152A; N192A and N198A / Q.
[0065] In certain embodiments, the CD80 protein variant comprises a second type of amino acid mutation at position N55 and / or N64.
[0066] In certain embodiments, the CD80 protein variant comprises a second type of amino acid mutation of N55A / Q and / or N64A.
[0067] In certain embodiments, the CD80 protein variant comprises at least one third type of amino acid mutation, and the amino acid mutation is capable of maintaining the affinity of the CD80 protein variant.
[0068] In certain embodiments, the CD80 protein variant comprises a third class amino acid mutation at one or more of the following amino acid positions: N55, N64, N152, and N198.
[0069] In certain embodiments, the CD80 protein variant comprises one or more of the following third class amino acid mutations: N55A / Q, N64A, N152A, and N198A.
[0070] In certain embodiments, the CD80 protein variant comprises a third type of amino acid mutation at position N192.
[0071] In certain embodiments, the CD80 protein variant comprises a third amino acid mutation of N192A.
[0072] In certain embodiments, the CD80 protein variant comprises at least one fourth amino acid mutation, which can enhance the binding of the CD80 protein variant to CD28 and / or PD-L1.
[0073] In certain embodiments, the CD80 protein variant comprises a fourth type of amino acid mutation at position N173 and / or N177.
[0074] In certain embodiments, the CD80 protein variant comprises a fourth type of amino acid mutation of N173Q and / or N177A.
[0075] In certain embodiments, the amino acid position numbers in the CD80 protein variant are determined with reference to the amino acid position numbers in SEQ ID NO: 1.
[0076] In certain embodiments, the CD80 protein variant comprises the amino acid sequence shown in any one of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23 and SEQ ID NO:24.
[0077] In certain embodiments, the CD80 protein variant is capable of binding to PD-L1, CD28 and / or CTLA-4.
[0078] In certain embodiments, the sialic acid content of the CD80 protein variant is greater than or equal to about 0.7.
[0079] On the other hand, the present application provides a fusion protein comprising the CD80 protein variant.
[0080] In certain embodiments, the fusion protein further comprises an immunoglobulin Fc region or a variant thereof.
[0081] In certain embodiments, the CD80 protein variant and the immunoglobulin Fc region in the fusion protein are directly or indirectly linked.
[0082] In certain embodiments, the immunoglobulin Fc region in the fusion protein comprises the Fc region of IgG.
[0083] In certain embodiments, the IgG in the fusion protein is selected from the group consisting of IgG1 and IgG4.
[0084] In certain embodiments, the CD80 protein variant in the fusion protein is located at the N-terminus or C-terminus of the immunoglobulin Fc region.
[0085] In certain embodiments, the immunoglobulin Fc region in the fusion protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 25 and SEQ ID NO: 26.
[0086] In certain embodiments, the fusion protein comprises the amino acid sequence shown in any one of SEQ ID NOs: 27-37.
[0087] On the other hand, the present application also provides a polypeptide comprising the CD80 protein variant or the fusion protein.
[0088] In another aspect, the present application provides one or more isolated nucleic acid molecules encoding the CD80 protein variant, the fusion protein, or the polypeptide described herein.
[0089] In another aspect, the present application provides a vector comprising the nucleic acid molecule described in the present application.
[0090] On the other hand, the present application provides a host cell comprising the nucleic acid molecule or the vector described in the present application.
[0091] On the other hand, the present application provides a method for preparing the CD80 protein variant or the fusion protein described in the present application, which comprises culturing the cells described in the present application under conditions that allow the fusion protein to be expressed.
[0092] On the other hand, the present application provides a pharmaceutical composition comprising the CD80 variant protein described herein, the fusion protein described herein, the polypeptide described herein, the nucleic acid molecule described herein, the vector described herein and / or the host cell described herein, and optionally a pharmaceutically acceptable carrier.
[0093] On the other hand, the present application provides a drug combination comprising the CD80 protein variant and an immune checkpoint inhibitor.
[0094] On the other hand, the present application provides a drug combination comprising the fusion protein and an immune checkpoint inhibitor.
[0095] On the other hand, the present application provides a drug combination comprising the polypeptide and an immune checkpoint inhibitor.
[0096] In certain embodiments, the immune checkpoints include PD-1, PD-L1, GITR and / or CTLA-4.
[0097] In certain embodiments, the immune checkpoints include one or more selected from the group consisting of: PD-1 antibody, PD-L1 antibody, CTLA-4 antibody, and GITR antibody.
[0098] In another aspect, the present application provides a method for regulating an immune response in a subject, comprising administering the CD80 protein variant, the fusion protein, or the polypeptide described herein.
[0099] In certain embodiments, the method of modulating an immune response in a subject comprises increasing an immune response.
[0100] In certain embodiments, in the method of modulating an immune response in a subject, the CD80 protein variant, the fusion protein, or the polypeptide exhibits increased binding affinity to PD-L1 compared to a wild-type CD80 protein or a fragment thereof.
[0101] In certain embodiments, in the method of modulating an immune response in a subject, the CD80 protein variant, the fusion protein, or the polypeptide exhibits increased binding affinity for CD28 compared to wild-type CD80 protein or a fragment thereof.
[0102] In certain embodiments, in the method of regulating an immune response in a subject, the CD80 protein variant, the fusion protein, or the polypeptide exhibits enhanced activity in activating T lymphocytes compared to wild-type CD80 protein or a fragment thereof.
[0103] On the other hand, the present application provides a use of the CD80 protein variant, the CD80 fusion protein, the polypeptide, the nucleic acid molecule, the vector, the host cell, the pharmaceutical composition, or the drug combination in the preparation of a method for preventing and / or treating a disease and / or condition.
[0104] In certain embodiments, the disease and / or condition comprises a tumor.
[0105] In certain embodiments, the tumor comprises a solid tumor and / or a hematological tumor.
[0106] In certain embodiments, the tumor comprises a tumor responsive to the expansion of central memory T cells.
[0107] In certain embodiments, the tumors described in the application include: malignant melanoma, breast cancer, gastric cancer, kidney cancer, non-small cell lung cancer, colon cancer, rectal cancer, head and neck squamous cell carcinoma, liver cancer, kidney cancer, mesothelioma, bladder cancer, pancreatic cancer, ovarian cancer, endometrial cancer and lymphoma.
[0108] On the other hand, the present application provides a method for preventing and / or treating a disease and / or condition, comprising administering the CD80 protein variant, the fusion protein, the polypeptide, the nucleic acid molecule, the vector, the host cell, the pharmaceutical composition or the pharmaceutical combination to a subject in need thereof.
[0109] In certain embodiments, the disease and / or condition comprises a tumor.
[0110] In certain embodiments, the tumor comprises a solid tumor and / or a hematological tumor.
[0111] In certain embodiments, the tumor comprises a tumor responsive to the expansion of central memory T cells.
[0112] On the other hand, the present application provides the CD80 protein variant, the fusion protein, the polypeptide, the nucleic acid molecule, the vector, the host cell, the pharmaceutical composition or the pharmaceutical combination, which is used for preventing and / or treating diseases and / or disorders.
[0113] In certain embodiments, the disease and / or condition comprises a tumor.
[0114] In certain embodiments, the tumor comprises a solid tumor and / or a hematological tumor.
[0115] In certain embodiments, the tumor comprises a tumor responsive to the expansion of central memory T cells.
[0116] In another aspect, the present application provides a method for detecting a CD80 binding ligand in a biological sample, comprising contacting the biological sample with a binding agent of the CD80 protein variant or the fusion protein described herein.
[0117] In certain embodiments, the method wherein the binding ligand comprises PD-L1, CD28 and / or CTLA-4.
[0118] On the other hand, the present application also provides a method for detecting the frequency and / or proliferation of central memory T cells in a subject, comprising administering the CD80 protein variant, the fusion protein, or the polypeptide.
[0119] In certain embodiments, the central memory T cells are CD95+ and CD28+ cells.
[0120] In certain embodiments, the central memory T cells are CD4+ central memory T cells and / or CD8+ central memory T cells.
[0121] On the other hand, the present application also provides a kit comprising the CD80 protein variant, the fusion protein, the polypeptide, the nucleic acid molecule, the vector, the host cell, the pharmaceutical composition or the pharmaceutical combination.
[0122] In certain embodiments, the kit is used to detect the frequency and / or proliferation of central memory T cells in a subject.
[0123] In certain embodiments, the kit is used to detect the presence and / or amount of a CD80 binding ligand in a biological sample.
[0124] On the other hand, the present application also provides the CD80 protein variant, the fusion protein, the polypeptide, the nucleic acid molecule, the vector, the host cell, the pharmaceutical composition or the drug combination, which is used to enhance the proliferation or frequency of central memory T cells.
[0125] Those skilled in the art can easily discern other aspects and advantages of the present application from the detailed description below. In the detailed description below, only exemplary embodiments of the present application are shown and described. As will be appreciated by those skilled in the art, the content of this application enables those skilled in the art to modify the disclosed specific embodiments without departing from the spirit and scope of the invention to which this application relates. Accordingly, the descriptions in the drawings and specification of this application are merely exemplary and not restrictive. BRIEF DESCRIPTION OF THE DRAWINGS
[0126] The specific features of the inventions of this application are set forth in the appended claims. The features and advantages of the inventions of this application can be better understood by referring to the exemplary embodiments described in detail below and the accompanying drawings. A brief description of the drawings is as follows:
[0127] FIG1 shows the structure of the CD80 fusion protein described in this application.
[0128] Figures 2A-2B show the activity detection results of the CD80 fusion protein described in this application binding to human PD-L1 protein.
[0129] Figures 3A-3D show the activity detection results of the CD80 fusion protein described in this application binding to human CTLA-4 protein.
[0130] Figures 4A-4C show the activity detection results of the CD80 fusion protein described in this application binding to human CD28 protein.
[0131] FIG5 shows the activity detection results of the CD80 fusion protein described in the present application binding to human CTLA-4 positive cells.
[0132] FIG6 shows the activity detection results of the CD80 fusion protein described in the present application binding to human PD-L1 positive cells.
[0133] FIG7 shows the activity detection results of the CD80 fusion protein described in the present application binding to human CD28 positive cells.
[0134] FIG8 shows the results of detecting the activity of the CD80 fusion protein described in the present application in activating T lymphocytes under aAPC / T mixed cell culture conditions.
[0135] Figures 9A-9C show the CD28 activation activity detection of the CD80 fusion protein described in this application.
[0136] FIG10 shows the anti-tumor activity results of the CD80 fusion protein described in the present application in the CT26 subcutaneous implantation model.
[0137] FIG11 shows the anti-tumor effect of the CD80 fusion protein described in this application in combination with a Treg inhibitor in a CT26 subcutaneous implantation model.
[0138] FIG12 shows the anti-tumor effect of the CD80 fusion protein described in this application in combination with a PD-1 inhibitor in a CT26 subcutaneous implantation model.
[0139] FIG13 shows the anti-tumor effect of the CD80 fusion protein described in this application in combination with a CTLA-4 inhibitor in a CT26 subcutaneous implantation model.
[0140] Figures 14A-14B show the results of cytokine release induced by the CD80 fusion protein described in this application.
[0141] FIG15 shows the charge heterogeneity analysis results of the CD80 fusion protein described in this application.
[0142] FIG16 shows the anti-tumor effects of the CD80 fusion proteins described in the present application with different sialic acid modification degrees.
[0143] Figure 17 shows the mean blood drug concentration-time curves of each group after a single intravenous infusion of CD80-WT-G1 and CD80M28 stock solutions in Sprague Dawley rats (Mean+SD, n=8) DETAILED DESCRIPTION
[0144] The following describes the implementation of the present invention through specific embodiments. People familiar with this technology can easily understand other advantages and effects of the present invention from the contents disclosed in this specification.
[0145] Definition of terms
[0146] In the present application, the term "CD80 protein variant" refers to a protein with an altered amino acid sequence relative to wild-type CD80. The wild-type CD80 generally refers to naturally occurring CD80 obtained from nature. In the present application, the wild-type CD80 may be human CD80. The variant generally refers to a substitution, deletion and / or addition of one or more amino acids in the sequence compared to the wild type. In some cases, the CD80 protein variant may be the extracellular domain (ECD) of the CD80 protein; further, the CD80 protein variant may be a protein in which one or more amino acid residues are mutated on the basis of the ECD; in some cases, the CD80 protein variant may be the IgV domain of the CD80 protein; further, the CD80 protein variant may be a protein in which one or more amino acid residues are mutated on the basis of the IgV domain. In some cases, the sequence number of the human CD80 in the GenBank database may be NP_005182.1.
[0147] In the present application, the term "extracellular domain (ECD) of CD80 protein" generally refers to a polypeptide fragment located on the surface of the cell membrane expressing the CD80 protein. The CD80 protein is a transmembrane glycoprotein comprising two Ig-like extracellular domains, a transmembrane helical segment and a short cytoplasmic tail. The Ig-like extracellular domain comprises a single V-type and C2-type domain. The extracellular domain of the CD80 protein may comprise all or part of the polypeptide fragments of two Ig-like extracellular domains. In the present application, the extracellular domain of the CD80 protein may refer to the extracellular domain of the human CD80 protein, for example, the extracellular domain of the CD80 protein described in the present application may be a protein domain comprising all or part of the amino acid sequence shown in SEQ ID NO: 1.
[0148] In the present application, the term "IgV domain of CD80 protein" generally refers to a polypeptide fragment of the V-type domain located on the surface of the cell membrane expressing the CD80 protein. The IgV domain of the CD80 protein may include all or part of the polypeptide fragment of the V-type domain. In the present application, the IgV domain of the CD80 protein may refer to the IgV domain of the human CD80 protein. For example, the IgV domain of the CD80 protein described in the present application may be a protein domain comprising all or part of the amino acid sequence shown in SEQ ID NO: 2.
[0149] In this application, the terms "PD-L1" and "PDL1" are used interchangeably, generally referring to programmed cell death ligand 1, which may also be referred to as surface antigen differentiation cluster 274 (CD274) or B7 homologous protein 1 (B7-H1), PDCD1L1, PDCD1LG1, PDL1, and belongs to the tumor necrosis factor superfamily. "PD-L1" can be complete PD-L1 and fragments thereof, and can be functional variants, isoforms, species homologs, derivatives, analogs of PD-L1, and analogs having at least one common epitope with PD-L1. PD-L1 can be a type I transmembrane glycoprotein composed of 290 amino acid residues, comprising an IgV-like region, an IgC-like region, a transmembrane hydrophobic region, and a 30-amino acid intracellular tail. In this application, the PD-L1 can be human PD-L1.
[0150] In this application, the term "CTLA-4" generally refers to cytotoxic T-lymphocyte antigen-4, which may also be referred to as CTLA4, surface antigen differentiation cluster 152 (CD152), which is a leukocyte differentiation antigen that shares the B7 molecule ligand with CD28 and belongs to the CD28 family of immunosuppressive receptors. CTLA-4 contains an extracellular V-type domain, a transmembrane domain, and a cytoplasmic tail. "CTLA-4" can be complete CTLA-4 and fragments thereof, and can be functional variants, isoforms, species homologs, derivatives, analogs of CTLA-4, and analogs having at least one common epitope with CTLA-4. In this application, the CTLA-4 can be human CTLA-4.
[0151] In this application, the term "CD28" generally refers to the surface antigen cluster of differentiation 28, which is a co-stimulatory molecule expressed on the surface of T lymphocytes. It is a receptor for CD80 and CD86 proteins, mediating the co-stimulation of T cells and promoting their survival, proliferation, and cytokine production. "CD28" can be complete CD28 and fragments thereof, and can be functional variants, isoforms, species homologs, derivatives, analogs of CD28, and analogs having at least one common epitope with CD28. In this application, the CD28 can be human CD28.
[0152] In this application, the term "amino acid mutation" generally refers to amino acid substitution, deletion, insertion and modification. Any combination of substitution, deletion, insertion and modification can be performed to achieve the final construct. In the present application, the amino acid mutation may be a replacement of at least one existing amino acid residue by another different amino acid residue (alternative amino acid residue), which may be a "naturally occurring amino acid residue" and is selected from the group consisting of: alanine (three letter code: ala, single letter code: A), arginine (arg, R), asparagine (asn, N), aspartic acid (asp, D), cysteine (cys, C), glutamine (gln, Q), glutamic acid (glu, E), glycine (gly, G), histidine (his, H), isoleucine (ile, I), leucine (leu, L)), lysine (lys, K), methionine (met, M), phenylalanine (phe, F), proline (pro, P), serine (ser, S), threonine (thr, T), tryptophan (trp, W), tyrosine (tyr, Y) and valine (val, V).
[0153] In the present application, amino acid positions are identified based on the amino acid sequence set forth in SEQ ID NO: 1 (amino acid sequence of the extracellular domain of human CD80 (UniProtKB / Swiss-Prot: P33681.1 sequence), i.e., positions 35-243 of the UniProtKB / Swiss-Prot: P33681.1 sequence). Specifically, the first amino acid in the amino acid sequence set forth in SEQ ID NO: 1 is numbered as the first amino acid.
[0154] In the present application, the extracellular domain of the CD80 protein may comprise amino acids 35-243 of the UniProtKB / Swiss-Prot: P33681.1 sequence.
[0155] In the present application, the IgV domain of the CD80 protein may comprise amino acids 35-140 of the UniProtKB / Swiss-Prot: P33681.1 sequence.
[0156] In the present application, the term "first class amino acid mutation" generally refers to an amino acid mutation that affects the stability of the CD80 protein variant. The stability of the CD80 protein variant refers to the ability of the CD80 protein variant to maintain approximately the same structure and function as the CD80 protein before mutation. The effect can be the maintenance, reduction and improvement of the stability of the CD80 protein variant. In the present application, the CD80 protein variant can be an amino acid sequence mutation based on the human CD80 protein. For example, in the present application, the first class amino acid mutation can include one or more amino acid mutations in all or part of the AA35-AA242 fragment of human CD80. In some cases, the one or more amino acid mutations can include amino acid mutations at any position selected from the following group: N55, N64, N152, N192 and N198.
[0157] In this application, the term "second-class amino acid mutation" generally refers to an amino acid mutation that affects the binding activity of the CD80 protein variant. The effect can be maintaining, reducing, or improving the binding activity of the CD80 protein variant. In this application, the CD80 protein variant can be an amino acid sequence mutation based on the human CD80 protein. For example, in this application, the second-class amino acid mutation can include one or more amino acid mutations in all or part of the AA35-AA242 fragment of human CD80. In some cases, the one or more amino acid mutations can include amino acid mutations at any position selected from the following group: N55, N64, N152, N192, and N198.
[0158] As used herein, the term "binding activity" generally refers to the ability of two binding sites to bind to each other. The binding site can be a region on a binding molecule, which can include a protein, enzyme substrate, second messenger, hormone, or allosteric modulator. In this application, binding activity can be the ability of a CD80 protein variant to bind to its ligand. Binding can be reversible (transient and non-covalent) or covalently reversible or irreversible.
[0159] In the present application, the term "third class amino acid mutation" generally refers to an amino acid mutation that affects the affinity of the CD80 protein variant. The effect can be maintaining, reducing, or improving the affinity of the CD80 protein variant. In the present application, the CD80 protein variant can be an amino acid sequence mutation based on the human CD80 protein. For example, in the present application, the third class amino acid mutation can include one or more amino acid mutations in all or part of the AA35-AA242 fragment of human CD80. In some cases, the one or more amino acid mutations can include amino acid mutations at any position selected from the following group: N55, N64, N152, N192, and N198.
[0160] In this application, the term "affinity" generally refers to the specific affinity that can cause two or more substances to interact with each other, and in some cases, it can be the affinity between a receptor and a ligand.
[0161] In the present application, the term "fourth type of amino acid mutation" generally refers to an amino acid mutation that affects the binding of the CD80 protein variant to CD28 and / or PD-L1. The effect can be the maintenance, reduction and improvement of the binding of the CD80 protein variant to CD28 and / or PD-L1. In the present application, the CD80 protein variant can be an amino acid sequence mutation based on the human CD80 protein. For example, in the present application, the third type of amino acid mutation can include one or more amino acid mutations in all or part of the AA35-AA242 fragment of human CD80. In some cases, the one or more amino acid mutations can include amino acid mutations at any position selected from the following group: N173 and / or N177.
[0162] In this application, the term "fusion protein" generally refers to a macromolecule formed by chemical and / or genetic fusion of two or more distinct protein molecules. A fusion protein can be the expression product of two or more genes recombined through DNA recombination technology, or a group of proteins that mediate the fusion of two or more cell membranes. In this application, a fusion protein can be a protein molecule containing these two domains, which is formed by genetically linking a target gene with an immunoglobulin Fc region or its variant fragment gene, and expressed in eukaryotic or prokaryotic cells.
[0163] In this application, the term "immunoglobulin Fc region" generally refers to the crystallizable segment of an immunoglobulin, which may include the CH2 and CH3 domains of immunoglobulins IgG, IgA, and IgD, or fragments thereof, and may include the CH2, CH3, and CH4 domains of IgM and IgE, or fragments thereof. For example, the IgG may include IgG1, IgG2, IgG3, or IgG4.
[0164] The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The term may be used to refer to an amino acid polymer in which one or more amino acid residues is a synthetic chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers, those containing modified residues, and non-naturally occurring amino acid polymers.
[0165] In this application, the term "nucleic acid molecule" generally refers to isolated forms of nucleotides, deoxyribonucleotides or ribonucleotides of any length, or their analogs, isolated from their natural environment or artificially synthesized.
[0166] In the present application, the term "vector" generally refers to a nucleic acid molecule that can self-replicate in a suitable host, and the nucleic acid molecule to be inserted is transferred to a cell (e.g., a host cell) and / or between cells. The vector may include a vector primarily for inserting DNA or RNA into a cell, a vector primarily for replicating DNA or RNA, and a vector primarily for the expression of transcription and / or translation of DNA or RNA. The vector also includes a vector with multiple above-mentioned functions. The vector may be a polynucleotide that can be transcribed and translated into a polypeptide when introduced into a suitable cell. Typically, the vector may produce an expression product of interest by cultivating a suitable cell comprising the vector. In the present application, the vector may be a plasmid.
[0167] In this application, the term "pharmaceutical composition" generally refers to a composition suitable for administration to a patient, which may be a human patient. For example, the pharmaceutical composition described herein may comprise the CD80 variant protein described herein, the fusion protein described herein, the nucleic acid molecule described herein, the vector described herein and / or the cell described herein, and optionally a pharmaceutically acceptable carrier. In addition, the pharmaceutical composition may further comprise a suitable formulation of one or more (pharmaceutically effective) carriers, stabilizers, excipients, diluents, solubilizers, surfactants, emulsifiers and / or preservatives. The acceptable ingredients of the composition are preferably non-toxic to the recipient at the dosage and concentration used. The pharmaceutical compositions of the present invention include, but are not limited to, liquid, frozen and lyophilized compositions.
[0168] In this application, the term "drug combination" generally refers to the use of two or more drugs in combination. In the drug combination, the different drug components can be mixed or placed separately. In the drug combination, the different drug components can be placed in the same container or in different containers. The different drug components in the drug combination can be administered simultaneously or separately, for example, the different drug components can be administered sequentially. In the drug combination, the different drug components can be administered in the same manner or in different manners.
[0169] As used herein, the term "pharmaceutically acceptable carrier" generally refers to any and all solvents, dispersion media, coatings, isotonic and absorption delaying agents, and the like that are compatible with pharmaceutical administration and are generally safe, non-toxic, and neither biologically nor otherwise undesirable.
[0170] In this application, the term "tumor" generally refers to a neoplasm or solid lesion formed by abnormal cell growth. In this application, a tumor can be a solid tumor or a non-solid tumor. In some cases, a tumor can include a tumor that responds to the proliferation of central memory T cells. In some cases, a tumor can include a tumor containing cells that are surface positive for CTLA-4.
[0171] In the present application, the proteins, polypeptides and / or amino acid sequences involved should also be understood to include at least the following scope: variants or homologs that have the same or similar functions as the proteins or polypeptides.
[0172] In the present application, the variant may be, for example, a protein or polypeptide in which one or more amino acids are substituted, deleted or added in the amino acid sequence of the protein and / or the polypeptide (e.g., CD80 protein variant). For example, the functional variant may comprise a protein or polypeptide having an amino acid change by at least 1, for example, 1-30, 1-20 or 1-10, for example, 1, 2, 3, 4 or 5 amino acid substitutions, deletions and / or insertions. The functional variant may substantially retain the biological properties of the protein or polypeptide before the change (e.g., substitution, deletion or addition). For example, the functional variant may retain at least 60%, 70%, 80%, 90%, or 100% of the biological activity (e.g., antigen binding ability) of the protein or polypeptide before the change. For example, the substitution may be a conservative substitution.
[0173] In the present application, the homolog can be a protein or polypeptide having at least about 85% (e.g., at least about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or more) sequence homology with the amino acid sequence of the protein and / or the polypeptide (e.g., CD80 protein variant).
[0174] In the present application, described homology generally refers to the similarity, similarity or association between two or more sequences.Can calculate " sequence homology per-cent " in the following manner: two sequences to be compared are compared in comparison window, determine that there is identical nucleic acid base (for example, A, T, C, G, I) or identical amino acid residue (for example, Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys and Met) number in the position to obtain the number of matching positions, with the number of matching positions divided by the total number of positions (that is, window size) in the comparison window, and result is multiplied by 100, to produce sequence homology per-cent.Comparison carried out in order to determine the sequence homology per-cent, can realize by several ways known in the art, for example, use publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximum alignment over the full length of the sequences being compared or within a region of interest. Homology can also be determined by the following methods: FASTA and BLAST. A description of the FASTA algorithm can be found in W. R. Earson and D. J. Lipman, "Improved tools for biological sequence comparison," Proc. Natl. Acad. Sci., 85: 2444-2448, 1988; and D. J. Lipman and W. R. Earson, "Rapid and sensitive protein similarity search," Science, 227: 1435-1441, 1989. A description of the BLAST algorithm can be found in S. Altschul, W. Gish, W. Miller, E. W. Myers, and D. Lipman, "A basic local alignment search tool," J. Mol. Biol., 215: 403-410, 1990.
[0175] In this application, the term "comprising" generally means including, encompassing, containing or encompassing. In some cases, it also means "being", "consisting of...".
[0176] In this application, the term "about" generally refers to a variation within a range of 0.5%-10% above or below the specified value, for example, a variation within a range of 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% above or below the specified value.
[0177] Detailed Description of the Invention
[0178] CD80 protein variants
[0179] In one aspect, the present application provides a CD80 protein variant, which may comprise a functionally active fragment of the CD80 protein or a variant thereof, wherein the variant has a mutation in one or more amino acid positions compared to the functionally active fragment of the corresponding wild-type CD80.
[0180] In the present application, the CD80 protein variant may have one or more of the following properties: 1) binding to PD-L1; 2) binding to CTLA-4; 3) binding to CD28; 4) activating the activity of T lymphocytes; and 5) inhibiting the growth and / or proliferation of tumors or tumor cells.
[0181] For example, the CD80 protein variant can simultaneously bind to PD-L1 and CD28 proteins. For example, the CD80 variant can simultaneously bind to PD-L1, CD28 and CTLA-4 proteins.
[0182] In the present application, the PD-L1 may be human PD-L1. In the present application, the CD28 may be human CD28. In the present application, the CTLA-4 may be human CTLA-4.
[0183] In the present application, the CD80 protein may be a human CD80 protein.
[0184] In the present application, the CD80 protein variant may comprise a functionally active fragment of CD80 or a variant thereof. For example, the functionally active fragment of CD80 may comprise the extracellular domain of CD80 protein or a fragment thereof. For example, the fragment of the extracellular domain of CD80 protein may comprise the IgV domain of CD80.
[0185] In the present application, the IgV domain of the wild-type CD80 protein may comprise the amino acid sequence shown in SEQ ID NO: 2.
[0186] In the present application, the extracellular domain of the wild-type CD80 protein may comprise the amino acid sequence shown in SEQ ID NO: 1.
[0187] In the present application, the variant of the IgV domain of the CD80 protein may comprise one or more amino acid mutations.
[0188] In the present application, the variant of the IgV domain of the CD80 protein may include the following amino acid sequence: VIHVTKEVKEVATLSCGHNVSVEELAQTRIYWQKEKKMVLTMMSGDMNIWPEYKNRTIFDITNX1LSIVILALRPSDEGTYECVVLKYEKDAFKREHLAEVTLSVKA. The variant of the IgV domain of the CD80 protein may include at least an amino acid substitution at X1.
[0189] In the present application, the IgV domain variant of the CD80 protein may comprise at least an amino acid substitution at position X1, compared to the IgV domain of the CD80 protein shown in SEQ ID NO: 2. For example, the amino acid at position X1 may be substituted with A.
[0190] In the present application, the extracellular domain variant of the CD80 protein may comprise one or more amino acid mutations.
[0191] In the present application, the extracellular domain variant of the CD80 protein may include the following amino acid sequence: VIHVTKEVKEVATLSCGHX1VSVEELAQTRIYWQKEKKMVLTMMSGDMNIWPEYKX2RTIFDITNX3LSIVILALRPSDEGTYECVVLKYEKDAFKREHLAEVTLSVKADFPTPSISDFEIPTSNIRRIICSTSGGFPEPHLSWLENGEELNAIX4TTVSQDPETELYAVSSKLDFX5MTTX6HSFMCLIKYGHLRVX7QTFNWX8TTKQEHFPDNL. The extracellular domain variant of the CD80 protein may include at least amino acid substitutions at X1, X2, X3, X4, X5, X6, X7 and / or X8.
[0192] For example, the CD80 protein variant may comprise an amino acid mutation at one or more positions of X1, X2, X3, X4, X5, X6, X7, and X8, wherein the amino acid at X1 may be substituted with A; the amino acid at X2 may be substituted with A or Q; the amino acid at X3 may be substituted with A; the amino acid at X4 may be substituted with A; the amino acid at X5 may be substituted with A or Q; the amino acid at X6 may be substituted with A; the amino acid at X7 may be substituted with A; and the amino acid at X8 may be substituted with A or Q.
[0193] In the present application, the CD80 protein variant may comprise a first type of amino acid mutation. For example, the first type of amino acid mutation can maintain the stability of the CD80 protein variant.
[0194] In the present application, the CD80 protein variant comprising the first type of amino acid mutation is compared with the extracellular domain of the CD80 protein shown in SEQ ID NO: 1. The extracellular domain variant of the CD80 protein may comprise at least amino acid substitutions at X2, X3, X4, X7 and / or X8, wherein the amino acid at X2 may be substituted with A or Q; the amino acid at X3 may be substituted with A; the amino acid at X4 may be substituted with A; the amino acid at X7 may be substituted with A; and the amino acid at X8 may be substituted with A or Q.
[0195] For example, the first type of amino acid mutation may include an amino acid mutation at position N64. In the present application, the first type of amino acid mutation may include amino acid mutations at positions N55 and N64. For example, the first type of amino acid mutation may include amino acid mutations at positions N55, N64 and N152. For example, the first type of amino acid mutation may include amino acid mutations at positions N55, N64 and N192. For example, the first type of amino acid mutation may include amino acid mutations at positions N55, N64 and N198. For example, the first type of amino acid mutation may include amino acid mutations at positions N55, N64, N152 and N198. For example, the first type of amino acid mutation may include amino acid mutations at positions N55, N64, N152 and N192.
[0196] For example, the first type of amino acid mutation may include an amino acid mutation of N64A. For example, the first type of amino acid mutation may include an amino acid mutation of N55A and N64A. For example, the first type of amino acid mutation may include an amino acid mutation of N55A, N64A, and N152A. For example, the first type of amino acid mutation may include an amino acid mutation of N55A, N64A, and N192A. For example, the first type of amino acid mutation may include an amino acid mutation of N55A, N64A, and N198A. For example, the first type of amino acid mutation may include an amino acid mutation of N55A, N64A, N152A, and N198A. For example, the first type of amino acid mutation may include an amino acid mutation of N55A, N64A, N152A, and N192A. For example, the first type of amino acid mutation may include an amino acid mutation of N55Q, N64A, N152A, and N198Q.
[0197] In the present application, the CD80 variant may comprise a second type of amino acid mutation. In the present application, the second type of amino acid mutation can maintain the binding activity of the CD80 protein variant.
[0198] In the present application, the CD80 protein variant comprising the second type of amino acid mutation is compared with the extracellular domain of the CD80 protein shown in SEQ ID NO: 1. The extracellular domain variant of the CD80 protein may comprise at least amino acid substitutions at X4, X7 and / or X8, wherein the amino acid at X4 may be substituted with A; the amino acid at X7 may be substituted with A; and the amino acid at X8 may be substituted with A and Q.
[0199] For example, the second type of amino acid mutations may include mutations at one or more amino acid positions N152, N192, and N198. For example, the second type of amino acid mutations may include one or more amino acid mutations N152A, N192A, and N198A / Q. For example, the second type of amino acid mutations may also include amino acid mutations at positions N55 and / or N64. For example, the second type of amino acid mutations may also include amino acid mutations N55A / Q and / or N64A.
[0200] In the present application, the CD80 protein variant may comprise a third type of amino acid mutation. In the present application, the third type of amino acid mutation can maintain the affinity of the CD80 protein variant.
[0201] In the present application, compared with the extracellular domain of the CD80 protein shown in SEQ ID NO: 1, the CD80 protein variant comprising the third type of amino acid mutation may comprise at least amino acid substitutions at X2, X3, X4 and / or X8, wherein the amino acid at X2 may be substituted with A or Q; the amino acid at X3 may be substituted with A; the amino acid at X4 may be substituted with A; and the amino acid at X8 may be substituted with A.
[0202] For example, the third category of amino acid mutations may include amino acid mutations at one or more of the following positions: N55, N64, N152, and N198. For example, the third category of amino acid mutations may include one or more of the following amino acid mutations: N55A / Q, N64A, N152A, and N198A. For example, the third category of amino acid mutations may also include an amino acid mutation at position N192. For example, the third category of amino acid mutations may also include an amino acid mutation at position N192A.
[0203] In the present application, the CD80 protein variant may comprise a fourth type of amino acid mutation. In the present application, the fourth type of amino acid mutation can enhance the binding of the CD80 protein variant to CD28 and / or PD-L1.
[0204] In the present application, the CD80 protein variant comprising the fourth type of amino acid mutation is compared with the extracellular domain of the CD80 protein shown in SEQ ID NO: 1. The extracellular domain variant of the CD80 protein may comprise at least amino acid substitutions at X5 and / or X6, wherein the amino acid at X5 may be substituted with Q; the amino acid at X6 may be substituted with A.
[0205] For example, the fourth type of amino acid mutation may comprise an amino acid mutation at position N173 and / or N177. For example, the fourth type of amino acid mutation may comprise an amino acid mutation at position N173Q and / or N177A.
[0206] In the present application, compared with the amino acid sequence shown in SEQ ID NO: 2, the CD80 protein variant may comprise an amino acid mutation at position N64. In the present application, compared with the amino acid sequence shown in SEQ ID NO: 1, the CD80 protein variant may comprise an amino acid mutation at positions N64 and N55. In the present application, compared with the amino acid sequence shown in SEQ ID NO: 1, the CD80 protein variant may comprise an amino acid mutation at positions N55, N64 and N152. In the present application, compared with the amino acid sequence shown in SEQ ID NO: 1, the CD80 protein variant may comprise an amino acid mutation at positions N55, N64 and N192. In the present application, compared with the amino acid sequence shown in SEQ ID NO: 1, the CD80 protein variant may comprise an amino acid mutation at positions N55, N64 and N198. In the present application, compared with the amino acid sequence shown in SEQ ID NO: 1, the CD80 protein variant may comprise an amino acid mutation at positions N55, N64, N152 and N198. In the present application, compared with the amino acid sequence shown in SEQ ID NO: 1, the CD80 protein variant may comprise amino acid mutations at positions N55, N64, N152 and N192. In the present application, compared with the amino acid sequence shown in SEQ ID NO: 1, the CD80 protein variant may comprise amino acid mutations at positions N55, N64, N152, N173, N177 and N198. In the present application, compared with the amino acid sequence shown in SEQ ID NO: 1, the CD80 protein variant may comprise amino acid mutations at positions N55, N64, N152, N173 and N198. In the present application, compared with the amino acid sequence shown in SEQ ID NO: 1, the CD80 protein variant may comprise amino acid mutations at positions N55, N64, N152, N177 and N198.
[0207] In the present application, compared with the amino acid sequence shown in SEQ ID NO: 1, the CD80 protein variant may comprise an amino acid mutation of N64A. In the present application, compared with the amino acid sequence shown in SEQ ID NO: 1, the CD80 protein variant may comprise an amino acid mutation of N55A and N64A. In the present application, compared with the amino acid sequence shown in SEQ ID NO: 1, the CD80 protein variant may comprise an amino acid mutation of N55A, N64A and N152A. In the present application, compared with the amino acid sequence shown in SEQ ID NO: 1, the CD80 protein variant may comprise an amino acid mutation of N55A, N64A and N192A. In the present application, compared with the amino acid sequence shown in SEQ ID NO: 1, the CD80 protein variant may comprise an amino acid mutation of N55A, N64A and N198A. In the present application, compared with the amino acid sequence shown in SEQ ID NO: 1, the CD80 protein variant may comprise amino acid mutations of N55A, N64A, N152A and N198A. In the present application, compared with the amino acid sequence shown in SEQ ID NO: 1, the CD80 protein variant may comprise amino acid mutations of N55A, N64A, N152A and N192A. In the present application, compared with the amino acid sequence shown in SEQ ID NO: 1, the CD80 protein variant may comprise amino acid mutations of N55Q, N64A, N152 and N198Q. In the present application, compared with the amino acid sequence shown in SEQ ID NO: 1, the CD80 protein variant may comprise amino acid mutations of N55Q, N64A, N152A, N173Q, N177A and N198Q. In the present application, the CD80 protein variant may comprise amino acid mutations N55Q, N64A, N152A, N173Q, and N198Q compared to the amino acid sequence shown in SEQ ID NO: 1. In the present application, the CD80 protein variant may comprise amino acid mutations N55Q, N64A, N152A, N177A, and N198Q compared to the amino acid sequence shown in SEQ ID NO: 1.
[0208] In the present application, the CD80 protein variant may comprise the amino acid sequence shown in any one of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23 and SEQ ID NO:24.
[0209] In the present application, the sialic acid content of the CD80 protein variant may be greater than or equal to about 0.7, greater than or equal to about 0.8, greater than or equal to about 0.9, greater than or equal to about 1.0, greater than or equal to about 1.1, greater than or equal to about 1.2, greater than or equal to about 1.3, greater than or equal to about 1.4, greater than or equal to about 1.5, greater than or equal to about 2, greater than or equal to about 3, greater than or equal to about 4, greater than or equal to about 5, greater than or equal to about 6, greater than or equal to about 7, greater than or equal to about 8, greater than or equal to about 95, greater than or equal to about 10, greater than or equal to about 11, greater than or equal to about 12, greater than or equal to about 13, or greater than or equal to about 14.
[0210] In the present application, the sialic acid content of the CD80 protein variant may be greater than or equal to about 0.7 and less than or equal to about 15, greater than or equal to about 0.8 and less than or equal to about 15, greater than or equal to about 0.9 and less than or equal to about 15, greater than or equal to about 1.0 and less than or equal to about 15, greater than or equal to about 1.1 and less than or equal to about 15, greater than or equal to about 1.2 and less than or equal to about 15, greater than or equal to about 1.3 and less than or equal to about 15, greater than or equal to about 1.4 and less than or equal to about 15, greater than or equal to about 1.5 and less than or equal to about 15, greater than or equal to about 2 and less than or equal to about 15. 15, approximately 3 or more and approximately 15 or less, approximately 4 or more and approximately 15 or less, approximately 5 or more and approximately 15 or less, approximately 6 or more and approximately 15 or less, approximately 7 or more and approximately 15 or less, approximately 8 or more and approximately 15 or less, approximately 9 or more and approximately 15 or less, approximately 10 or more and approximately 15 or less, approximately 11 or more and approximately 15 or less, approximately 12 or more and approximately 15 or less, approximately 13 or more and approximately 15 or less, or approximately 14 or more and approximately 15 or less.
[0211] Fusion protein
[0212] In another aspect, the present application provides a fusion protein comprising a CD80 protein variant. In the present application, the fusion protein may further comprise other functional fragments. For example, the fusion protein may comprise the CD80 protein variant and an immunoglobulin Fc region or a variant thereof.
[0213] In the present application, the immunoglobulin Fc region may comprise the Fc region of an IgG, which may be a human IgG, and the human IgG may be human IgG1 and / or human IgG4. The variant may be a full or partial amino acid fragment of an immunoglobulin Fc region. For example, the immunoglobulin Fc region may comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 25 or SEQ ID NO: 26. For example, the IgG1 Fc region may comprise the amino acid sequence set forth in SEQ ID NO: 25. For example, the IgG4 Fc region may comprise the amino acid sequence set forth in SEQ ID NO: 26.
[0214] In the present application, the CD80 protein variant and the immunoglobulin Fc region can be directly or indirectly linked. The indirect linking mentioned in the present application includes linking via a polypeptide linker.
[0215] In the present application, the polypeptide linker may include an amino acid sequence consisting of one or more amino acid residues, and the amino acid residue may include proline or cysteine. The linker may connect two binding fragments, and the binding fragments may include the same or different fragments. For example, the linker may connect the CD80 protein variant and the immunoglobulin Fc region. For example, the linker may include an amino acid sequence of (GGGGS)n, wherein n can be any positive integer from 1 to 10. For example, n can be 1 to 4. For example, the linker may include an amino acid sequence of (GGGGS)2. For example, the linker may include an amino acid sequence of (GGGGS)3. For example, the linker may include an amino acid sequence of (GGGGS)4.
[0216] In the present application, the fusion protein may comprise a first polypeptide chain or a second polypeptide chain.
[0217] In the present application, the polypeptide fragment of the first polypeptide chain can be sequentially from N-terminus to C-terminus: CD80 protein variant-linker-immunoglobulin Fc region, the CD80 protein variant can be connected to the linker, and the linker can be connected to the N-terminus of the immunoglobulin Fc region.
[0218] In the present application, the polypeptide fragment of the second polypeptide chain may be sequentially from N-terminus to C-terminus: CD80 protein variant-immunoglobulin Fc region, and the CD80 protein variant may be connected to the N-terminus of the immunoglobulin Fc region.
[0219] In the present application, the fusion protein may comprise two identical first polypeptide chains, or may comprise two identical second polypeptide chains.
[0220] For example, the first polypeptide chain or the second polypeptide chain may comprise a CD80 protein variant sequence as set forth in any one of SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24. For example, the first polypeptide chain or the second polypeptide chain may comprise an amino acid sequence as set forth in any one of SEQ ID NOs: 27-37.
[0221] In the present application, the fusion protein comprises the CD80 protein variant and other protein molecules / polypeptide molecules. For example, the other protein molecules / polypeptide molecules do not affect the function of the CD80 protein variant.
[0222] Nucleic acid, vector, host cell and preparation method
[0223] In another aspect, the present application also provides one or more isolated nucleic acid molecules that encode the CD80 protein variants and fusion proteins thereof described herein. For example, each of the one or more nucleic acid molecules can encode the entire CD80 protein variant or fusion protein thereof, or a portion thereof.
[0224] The nucleic acid molecules described herein can be isolated. For example, they can be produced or synthesized by the following methods: (1) amplified in vitro, such as by polymerase chain reaction (PCR) amplification; (2) produced by cloning and recombination; (3) purified, such as by enzyme digestion and gel electrophoresis fractionation, or (4) synthesized, such as by chemical synthesis. For example, the isolated nucleic acid can be produced by polymerase chain reaction (PCR) amplification. In the present application, nucleic acids encoding the CD80 protein variants and their fusion proteins can be prepared by various methods known in the art.
[0225] On the other hand, the application provides one or more vectors, which comprise one or more nucleic acid molecules described herein. One or more nucleic acid molecules can be included in each vector. In addition, other genes can also be included in the vector, such as marker genes that allow the selection of the vector in a suitable host cell and under appropriate conditions. In addition, the vector can contain multiple elements for controlling expression, including promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes. In addition, the vector can also contain a replication initiation site. In addition, the vector can include, for example, plasmids, cosmids, viruses, phages, or other vectors commonly used in, for example, genetic engineering.
[0226] On the other hand, the application provides host cells, and the host cells can include one or more nucleic acid molecules and / or one or more vectors described in the application. In some embodiments, every kind or each host cell can include one or a nucleic acid molecule or vector described in the application. In some embodiments, every kind or each host cell can include multiple (for example, 2 or more) or multiple (for example, 2 or more) nucleic acid molecules or vector described in the application. For example, the vector described in the application can be introduced into the host cell, such as prokaryotic cells (for example, bacterial cells), Chinese hamster ovary celI, NS / 0 cells, HEK293 cells, or other eukaryotic cells, such as cells, fungi or yeast cells from plants etc. The vector described in the application can be introduced into the host cell by methods known in the art, such as electroporation, lipofectine transfection, lipofectamin transfection etc.
[0227] In another aspect, the present application provides methods for preparing the CD80 protein variants and fusion proteins thereof described herein. The methods may include culturing the host cells described herein under conditions that allow for expression of the CD80 protein variants and fusion proteins thereof. For example, the methods may be performed using an appropriate culture medium, at an appropriate temperature and for an appropriate time, as is known to those skilled in the art.
[0228] In some cases, the method may further include a step of harvesting (e.g., isolating and / or purifying) the CD80 protein variants and fusion proteins described herein. For example, affinity chromatography using protein G-agarose, protein A-agarose, or metal chelation can be employed. The CD80 protein variants and fusion proteins described herein can also be purified and isolated by gel electrophoresis and / or high-performance liquid chromatography.
[0229] Pharmaceutical compositions, drug combinations, and applications
[0230] On the other hand, the present application provides a pharmaceutical composition, which may comprise the CD80 protein variant and its fusion protein described in the present application, the nucleic acid molecule, the vector, the host cell, and optionally a pharmaceutically acceptable carrier.
[0231] The pharmaceutically acceptable carrier may include a buffer, an antioxidant, a preservative, a low molecular weight polypeptide, a protein, a hydrophilic polymer, an amino acid, a sugar, a chelating agent, a counter ion, a metal complex and / or a nonionic surfactant, etc.
[0232] In the present application, the pharmaceutical composition can be formulated for oral administration, intravenous administration, intramuscular administration, in situ administration at the tumor site, inhalation, rectal administration, vaginal administration, transdermal administration or administration via a subcutaneous reservoir. The pharmaceutical composition can be used to inhibit tumor growth. For example, the pharmaceutical composition of the present application can inhibit or delay the development or progression of a disease, can reduce tumor size (or even substantially eliminate the tumor), and / or can alleviate and / or stabilize the disease state.
[0233] The pharmaceutical compositions described herein may comprise a prophylactically and / or therapeutically effective amount of the CD80 protein variants and fusion proteins thereof. The prophylactically and / or therapeutically effective amount is a dose required to prevent and / or treat (at least partially treat) a disease or condition and / or any complications thereof in a subject suffering from or at risk of developing the disease or condition.
[0234] On the other hand, the present application provides a drug combination, which may include the CD80 protein variant and an immune checkpoint inhibitor.
[0235] On the other hand, the present application provides a drug combination, which may include the fusion protein and an immune checkpoint inhibitor.
[0236] In the present application, the immune checkpoints may include PD-1, PD-L1, GITR and / or CTLA-4.
[0237] In the present application, the immune checkpoint inhibitor may include one or more selected from the following group: PD-1 antibody, PD-L1 antibody, CTLA-4 antibody, GITR antibody.
[0238] In the present application, the PD-1 antibody can be selected from: nivolumab, pembrolizumab, toripalimab, sintilimab, carrelizumab, and genoluzumab.
[0239] In the present application, the PD-L1 antibody can be selected from: durvalumab, atezolizumab, envoralizumab, adebelimumab, sugemalimab, and teterizumab.
[0240] In the present application, the CTLA-4 antibody can be selected from: ipilimumab, tremelimumab.
[0241] In the present application, the GITR antibody can be selected from: MK-4166, TRX-518, INCAGN01876, BMS-986156, AMG228, IBI102, ASP-1951.
[0242] The above antibodies are only examples. As long as such antibodies can functionally act as inhibitors of the corresponding immune checkpoints, they can be used in this application.
[0243] In the pharmaceutical combination of the present application, the CD80 protein variant / fusion protein may be present in the same container as the immune checkpoint inhibitor. In the pharmaceutical combination of the present application, the CD80 protein variant / fusion protein may be present in different containers as the immune checkpoint inhibitor.
[0244] In the present application, the CD80 protein variant / fusion protein and the immune checkpoint inhibitor can be administered simultaneously. Simultaneous administration can be administration of the components mixed together or separately. They can be administered in the same manner, such as into the same vein or other blood vessel, or in different manners, such as simultaneous intravenous and intratumoral administration.
[0245] In the present application, the CD80 protein variant / fusion protein and the immune checkpoint inhibitor can be administered sequentially. The order of administration can be to administer the CD80 protein variant / fusion protein first and then the immune checkpoint inhibitor; or to administer the immune checkpoint inhibitor first and then the CD80 protein variant / fusion protein. It can be administered in the same manner or in different manners. Each component can be administered once or in multiple doses. In certain embodiments, sequential administration can be administered at any time interval, including minutes, hours, days, weeks, months or years. In certain embodiments, sequential administration refers to administration separated by a time interval of at least 2 minutes, 5 minutes, 10 minutes, 30 minutes, 1 hour, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 1 month, 6 weeks, 2 months, 3 months, 4 months, 5 months or 6 months.
[0246] On the other hand, the present application provides use of the CD80 protein variant and its fusion protein in the preparation of a drug for preventing or treating a disease or disorder.
[0247] In another aspect, the present application provides the CD80 protein variant and its fusion protein, which are used to prevent or treat diseases or disorders.
[0248] In another aspect, the present application provides a method for preventing or treating tumors, comprising administering the CD80 protein variants and fusion proteins thereof described herein to a subject in need thereof. In the present application, colorectal cancer may also be included.
[0249] In the present application, the tumor may include a solid tumor. In the present application, the tumor may include a non-solid tumor. In the present application, the tumor may include one or more selected from the group consisting of: malignant melanoma, breast cancer, gastric cancer, kidney cancer, non-small cell lung cancer, colon cancer, rectal cancer, head and neck squamous cell carcinoma, liver cancer, kidney cancer, mesothelioma, bladder cancer, pancreatic cancer, ovarian cancer, endometrial cancer, and lymphoma.
[0250] Without intending to be bound by any theory, the following examples are merely intended to illustrate the variants, fusion proteins, preparation methods and uses of the present application, and are not intended to limit the scope of the invention of the present application.
[0251] Example
[0252] Example 1 Preparation of CD80 fusion protein
[0253] The CD80 fusion protein is obtained by linking the CD80 extracellular domain or its variant to the N-terminus of the Fc fragment of human IgG1 (amino acid sequence number: SEQ ID NO: 25), wherein the CD80 extracellular domain or its variant includes: wild-type CD80 ECD (SEQ ID NO: 1, wild-type CD80 extracellular domain), M12 (SEQ ID NO: 6), M13 (SEQ ID NO: 7), M14 (SEQ ID NO: 8), M15 (SEQ ID NO: 9), M16 (SEQ ID NO: 10), M18 (SEQ ID NO: 11), M19 (SEQ ID NO: 12), M20 (SEQ ID NO: 13), M21 (SEQ ID NO: 14), M22 (SEQ ID NO: 15), M23 (SEQ ID NO: 16), M24 (SEQ ID NO: 17), M25 (SEQ ID NO: 18), M26 (SEQ ID NO: 19), M27 (SEQ ID NO: 20), M28 (SEQ ID NO: 21), M29 (SEQ ID NO: 30), M31 (SEQ ID NO: 31), M32 (SEQ ID NO: 32), M33 (SEQ ID NO: 33), M34 (SEQ ID NO: 34), M35 (SEQ ID NO: 35), M36 (SEQ ID NO: 36), M37 (SEQ ID NO: 37), M38 (SEQ ID NO: 38), M39 (SEQ ID NO: 40), M40 (SEQ ID NO: 41), M41 (SEQ ID NO: 42), M42 (SEQ ID NO: 43), M43 (SEQ ID NO: 44), M44 (SEQ ID NO: ID NO: 21), M29 (SEQ ID NO: 22), M30 (SEQ ID NO: 23), M31 (SEQ ID NO: 24). The CD80 protein IgV domain or its variants include: wild-type CD80IgV (SEQ ID NO: 2), M09 (SEQ ID NO: 3), M10 (SEQ ID NO: 4), M11 (SEQ ID NO: 5).
[0254] The above-mentioned CD80 extracellular domain or its variants were respectively connected to the N-terminus of the Fc fragment of human IgG1 (amino acid sequence number: SEQ ID NO: 25) to obtain CD80 fusion proteins, which were respectively named: CD80-WT, CD80M12, CD80M13, CD80M14, CD80M15, CD80M16, CD80M18, CD80M19, CD80M20, CD80M21, CD80M22, CD80M23, CD80M24, CD80M25, CD80M26, CD80M27, CD80M28, CD80M29, CD80M30, CD80M31, CD80-IgV, CD80M09, CD80M10, and CD80M11.
[0255] The specific structure of CD80 fusion protein is shown in FIG1 .
[0256] Among them, CD80M12, CD80M11, CD80M14, CD80M15, CD80M16, CD80M26, CD80M27, CD80M28, CD80M29, CD80M30, and CD80M31 are stably expressed with moderate expression levels; they have good binding activity with PD-L1, CTLA-4, and / or CD28 and can maintain affinity with PD-L1, CTLA-4, and / or CD28.
[0257] Example 2 Detection of the activity of CD80 fusion protein binding to human PD-L1, CTLA-4, and CD28 proteins
[0258] (1) Using CD80-WT as a control, ELISA was used to evaluate the binding activity of CD80 fusion protein to PD-L1.
[0259] ELISA plates were coated with PD-L1 (Human PD-L1 / B7-H1 / CD274 Protein (His Tag, Sino Biological)) at 4°C overnight. After washing with PBST, 10% fetal bovine serum was added and the plates were blocked at 37°C for 1 hour. Different concentrations of CD80 fusion protein were added and reacted at 37°C for 1 hour. After washing with PBST, goat anti-human IgG Fc antibody (horseradish peroxidase (HRP) conjugate, affinity purified, Invitrogen) was added and reacted at 37°C for 30 minutes. The plates were washed five times with PBST. 100 μL of TMB (eBioscience) was added to each well and the plates were incubated at room temperature (20 ± 5°C) in the dark for 1–2 minutes. Subsequently, 100 μL of 2N H2SO4 stop solution was added to each well to terminate the substrate reaction. The OD values were read at 450 nm on a microplate reader to analyze the binding ability of CD80 fusion protein to PD-L1.
[0260] The results are shown in Figures 2A-2B, which show that under high concentration conditions, the binding activity of the CD80 protein variant described in this application to PD-L1 is significantly stronger than that of CD80-WT.
[0261] (2) Using CD80-WT as a control, the binding activity of CD80 fusion protein to CTLA-4 was evaluated by ELISA.
[0262] ELISA plates were coated with CTLA-4 (Human CTLA-4 / CD152 Protein, ACROBiosystems) at 4°C overnight. After washing with PBST, 10% fetal bovine serum was added and the plates were blocked at 37°C for 1 hour. Different concentrations of CD80 fusion protein were added and reacted at 37°C for 1 hour. After washing with PBST, goat anti-human IgG Fc antibody (horseradish peroxidase (HRP) conjugate, affinity purified, Invitrogen) was added and reacted at 37°C for 30 minutes. The plates were washed five times with PBST. 100 μL of TMB (eBioscience) was added to each well and the plates were incubated at room temperature (20±5°C) in the dark for 1–2 minutes. Subsequently, 100 μL of 2N H2SO4 stop solution was added to each well to terminate the substrate reaction. The OD values were read at 450 nm on a microplate reader to analyze the binding ability of CD80 fusion protein to CTLA-4.
[0263] The results are shown in Figures 3A-3C. The results in Figure 3A show that except for CD80M09, CD80M10, CD80M11, CD80M19, and CD80M20, whose binding was significantly weaker than that of wild-type CD80-WT, the binding activity of the remaining variants to CTLA-4 was comparable to that of CD80WT.
[0264] (3) Using CD80-WT as a control, the binding activity of CD80 fusion protein to CD28 was evaluated by ELISA.
[0265] ELISA plates were coated with human CD28 (Sino Biological) at 4°C overnight. After washing with PBST, 10% fetal bovine serum was added and the plates were blocked at 37°C for 1 hour. Different concentrations of CD80 fusion protein were added and reacted at 37°C for 1 hour. After washing with PBST, goat anti-human IgG Fc antibody (horseradish peroxidase (HRP) conjugate, affinity purified, Invitrogen) was added and reacted at 37°C for 30 minutes. The plates were washed five times with PBST. 100 μL of TMB (eBioscience) was added to each well and the plates were incubated at room temperature (20 ± 5°C) in the dark for 1–2 minutes. Subsequently, 100 μL of 2N H2SO4 stop solution was added to each well to terminate the substrate reaction. The OD values were read at 450 nm on a microplate reader to analyze the binding ability of CD80 fusion protein to CD28.
[0266] The results are shown in Figures 4A-4C, which show that the binding activity of CD80M11, CD80M23, CD80M25, CD80M27, CD80M29, CD80M30, and CD80M31 to CD28 was significantly stronger than that of CD80-WT, and the binding activity of the remaining fusion proteins was similar to that of CD80-WT.
[0267] Example 3 Activity detection of CD80 fusion protein binding to human PD-L1, CTLA-4, and CD28 positive cells
[0268] (1) Using CD80-WT as a control, FACS evaluated the binding of CD80 fusion protein to CTLA-4 positive cells
[0269] CHOK1 cells overexpressing human CTLA-4 (CHOK1-CTLA-4) were collected and 5×10 5Cells were added to 1.5 mL EP tubes; different concentrations of CD80 fusion protein were added and incubated on ice in the dark for 30 minutes; after washing with FACS buffer, PE fluorescent-labeled goat anti-human IgG Fc secondary antibody (Invitrogen) was added and incubated on ice in the dark for 30 minutes; washed twice with FACS buffer; 400 μL of 1% paraformaldehyde fixative (Solarbio) was added to each tube to fix the cells, mixed well, and the positive rate of PE fluorescence was detected by an analyzer to analyze the binding ability of CD80 fusion protein to CTLA-4-positive cells.
[0270] The results are shown in FIG5 , which show that CD80M28 and CD80-WT have similar abilities to bind to cell surface CTLA-4.
[0271] (2) Using CD80-WT as a control, FACS evaluated the binding of CD80 fusion protein to PD-L1-positive cells
[0272] CHOK1 cells overexpressing human PD-L1 (CHOK1-PD-L1) were collected and 5×10 5 Cells were added to 1.5 mL EP tubes; different concentrations of CD80 fusion protein were added and incubated on ice in the dark for 30 minutes; after washing with FACS buffer, PE fluorescent-labeled goat anti-human IgG Fc secondary antibody (Invitrogen) was added and incubated on ice in the dark for 30 minutes; washed twice with FACS buffer; 400 μL of 1% paraformaldehyde fixative (Solarbio) was added to each tube to fix the cells, mixed well, and the positive rate of PE fluorescence was detected by an analyzer to analyze the binding ability of CD80 fusion protein to PD-L1-positive cells.
[0273] The results are shown in Figure 6, which show that CD80M28 has a stronger ability to bind to cell surface PD-L1 than CD80-WT.
[0274] (3) Using CD80-WT as a control, FACS evaluated the binding of CD80 fusion protein to CD28-positive cells
[0275] CHOK1 cells overexpressing human CD28 (CHOK1-CD28) were collected and plated at a volume of 5 × 10 cells per tube. 5Cells were added to 1.5 mL EP tubes; various concentrations of CD80 fusion protein were added and incubated on ice in the dark for 30 min; after washing with FACS buffer, PE fluorescent-labeled goat anti-human IgG Fc secondary antibody (Invitrogen) was added and incubated on ice in the dark for 30 min; washed twice with FACS buffer; fixed the cells with 400 μL of 1% paraformaldehyde fixative (Solarbio) and mixed thoroughly. The PE fluorescence positivity rate was detected by an analyzer to analyze the binding ability of CD80 fusion protein to CD28-positive cells.
[0276] The results are shown in FIG7 , which show that CD80M28 has a slightly stronger ability to bind to cell surface CD28 than CD80-WT.
[0277] Example 4 Detection of the activity of CD80 fusion protein in activating T lymphocytes using aAPC / T mixed cell culture
[0278] The activity of CD80 fusion protein in activating T lymphocytes was evaluated in an experimental system of mixed culture of aAPCs and CD4+ T lymphocytes, using CD80 fusion proteins CD80-Fc and IgG1-Fc proteins as controls, 293T cells overexpressing OKT3scFv and CD64 (293T-OKT3-CD64) as antigen-presenting cells (artificial APCs, aAPCs), and CD4+ T lymphocytes as effector cells.
[0279] 293T-OKT3-CD64 cells were collected and 2.5×10 cells were added to each well. 4 Cells were added into 96-well cell culture plates; PBMC cells from healthy donors (MT-BIO) were separated using CD4+ T cell isolation kit (CD4+ T Cell Isolation Kit, human, Miltenyi Biotec) to obtain CD4+ T lymphocytes, and 5×10 4Cells were added to a 96-well cell culture plate; then 1200 nM CD80 fusion protein, IgG1-Fc protein (Human IgG1 Fc Protein, Tag Free, ACROBiosystems) and CD80 fusion protein CD80-Fc (Human B7-1 / CD80 Protein, Fc Tag, ACROBiosystems) were added, and the cells were incubated in a 37°C incubator for 24 hours, and the supernatant was collected. The IL-2 level in the cell supernatant was detected using an IL-2 ELISA kit (HUMAN IL-2 ELISA KIT, ExCell Bio) to analyze the activity of CD80 fusion protein in activating T lymphocytes in the aAPC / T cell mixed culture system.
[0280] The results shown in Figure 8 show that CD80-WT, CD80M26, CD80M27, and CD80M28 can activate lymphocytes in APC / T mixed cells, and the activation activity is similar to that of the CD80 molecule.
[0281] Example 5: Evaluation of CD28 signaling pathway activation activity of fusion protein by reporter gene method
[0282] FCGR2B / TCR Activator / CHO (FCGR2B / CHO) cells were collected and cultured at a rate of 1.5×10 4 Cells / well were added to a 96-well white / clear bottom plate (Thermo). Different concentrations of fusion protein were added to the cells; 2.5×10 4 CD28 Effector Reporter (abbreviated as CD28 effector) effector cells were added to each well, and the 96-well plate was placed in a 37°C 5% CO2 incubator for 5.5 hours; 120 μL of luciferase detection reagent (Bright-Lumi TM Firefly luciferase reporter gene detection kit (Biyuntian) was used. After incubation at room temperature in the dark for 10 min, the relative fluorescence intensity of chemiluminescence was measured by a multifunctional microplate reader to analyze the CD28 activation activity mediated by the fusion protein in the FCGR2B / CHO cell + CD28effector cell system.
[0283] The results are shown in Figures 9A-9C , which show that all fusion proteins have CD28 activation activity, the activity of CD80M28 is stronger than that of CD80-WT, and the activities of CD80M12, CD80M14, CD80M16, CD80M26, CD80M30, and CD80M31 are close to that of CD80-WT.
[0284] Example 6 Evaluation of the anti-tumor activity of CD80 fusion protein using the CT26 subcutaneous implantation model
[0285] The experimental mice were subcutaneously inoculated with 5×10 5 CT26 cells were resuspended in PBS (0.1 ml / cell). Tumor growth was observed regularly and the cells were kept in a PBS container until the tumor grew to an average volume of approximately 76 mm. 3 Mice were randomly divided into five groups of six mice each based on tumor size and body weight. Group G1 received CD80M28 at 2 mg / kg, Group G2 received CD80M28 at 0.5 mg / kg, Group G3 received CD80M28 at 0.1 mg / kg, Group G4 received CD80-WTG1 at 0.5 mg / kg, and Group G5 served as the vehicle control. All mice were intraperitoneally administered three times per week for a total of three doses.
[0286] On Day 22, some mice in the vehicle control group had tumors exceeding 3000 mm 3 The mean tumor volume of the vehicle control group (G5) on Day 22 was 2189.79 mm3, and the mean tumor volume of the CD80M282 mg / kg TIW group on Day 22 was 865.57 mm3. 3 The relative tumor inhibition rate (TGI) was 60.47%, which was significantly different from the control group (p<0.05). The average tumor volume of the CD80M28 0.5mg / kg TIW group on Day 22 was 877.01mm 3 The relative tumor inhibition rate (TGI) was 59.95%, which was significantly different from the control group (p<0.05). The average tumor volume of the CD80M28 0.1mg / kg TIW group on Day 22 was 1507.25mm 3 The relative tumor inhibition rate (TGI) was 31.17%, which was not significantly different from the control group. The CD80-WTG1 0.5 mg / kg TIW group had an average tumor volume of 1337.30 mm³ on Day 22, with a relative tumor inhibition rate (TGI) of 38.93%, which was not significantly different from the control group. Mice in all groups maintained normal body weight, showed no abnormalities, and were in good general condition.
[0287] As shown in FIG10 , the results showed that CD80M28 inhibited tumor growth in a dose-dependent manner, and its activity was significantly better than that of wild-type CD80-WT at the same dose.
[0288] Example 7 Evaluation of the anti-tumor effect of CD80 fusion protein combined with Treg inhibitors using the CT26 subcutaneous implant model
[0289] Taking anti-GITR antibody as an example, the synergistic anti-tumor effect of CD80 fusion protein and Treg inhibitor was explored.
[0290] The anti-GITR antibody disclosed in WO2017096189A1 was combined with the fusion protein of the present application to study the synergistic effect of the two. Mouse colorectal cancer cells CT26 were inoculated subcutaneously in the right anterior flank of female PD1 / GITR double humanized mice. 3 The mice were divided into groups and dosed at about 1 hour. There were 6 groups with 5 mice in each group, namely G1: vehicle group, G2: CD80M28 (3 mg / kg) group, G3: CD80-WT (3 mg / kg) group, G4: anti-GITR antibody (10 mg / kg) group, G5: CD80M28 + anti-GITR antibody (3 + 10 mg / kg) group, G6: CD80-WT + anti-GITR antibody (3 + 10 mg / kg) group. CD80-WT and CD80M28 were administered intravenously three times a week, and anti-GITR antibody was injected intraperitoneally twice a week for two weeks. Tumor volume and body weight were measured every week, and the changes in body weight and tumor volume of tumor-bearing mice and the relationship with the administration time were recorded. The tumor growth inhibition rate TGI was calculated. TV (%) and statistical analysis was performed.
[0291] The results are shown in Figure 11. The tumor growth inhibition rates of CD80M28, CD80-WT, anti-GITR antibody, CD80M28 + anti-GITR antibody, and CD80-WT + anti-GITR antibody were 86.43%, 64.57%, 69.98%, 89.06%, and 80.80%, respectively. The tumor volumes in each treatment group were significantly lower than those in the vehicle control group (p < 0.05), demonstrating significant anti-tumor effects and effectively inhibiting tumor growth. The tumor volume in the CD80M28 + anti-GITR antibody combination treatment group was the smallest among all treatment groups, and the combination treatment group exhibited superior tumor inhibition activity to the single-drug group.
[0292] Example 8 Evaluation of the anti-tumor effect of the combination of fusion protein and anti-PD-1 antibody using the CT26 subcutaneous implant model
[0293] The synergistic effect of the combined use of the CD80 fusion protein of the present application and the anti-m-PD-1 antibody was studied. The anti-m-PD-1 antibody used in the study was purchased from Bioxcell, catalog number BP0146.
[0294] Mouse colorectal cancer cells CT26 were inoculated subcutaneously in the right anterior flank of female Balb / c mice. On the 6th day after inoculation, the average tumor volume was approximately 70.9 mm 3Tumor-bearing mice were randomly divided into four groups using the randomized block method: Group 1 (PBS group, Group 1), Group 2 (CD80M28 (0.4 mg / kg) group, Group 3 (anti-mPD-1 antibody (5 mg / kg) group, Group 3), and Group 4 (anti-mPD-1 antibody (5 mg / kg) + CD80M28 (0.4 mg / kg) group, Group 4), with six mice in each group. The dosage volume for each group was 10 mL / kg. Groups 1 and 2 were administered via tail vein injection three times per week for one week; Group 3 was administered intraperitoneally twice per week for two weeks, for a total of four doses; and Group 4 received a combination of intraperitoneal injections of anti-mPD-1 antibody (5 mg / kg) twice per week for two weeks and CD80M28 (0.4 mg / kg) three times per week for one week, for a total of seven doses.
[0295] The results are shown in Figure 12. The results show that on the 18th day after the start of drug administration, the tumor volume of Group 1 was 2264.23±514.76mm 3 The tumor volume of Group 3 was 1109.87±224.72mm 3 The tumor volume inhibition rate (TGI) was 52.64%, which was not significantly different from that of the control group (P>0.05). The tumor volume of Group 2 was 821.79±387.96mm 3 The tumor volume inhibition rate (TGI) was 65.76%, which was statistically different from that of the control group (P < 0.05). The tumor volume of Group 4 was 140.49 ± 34.58 mm 3 The tumor volume inhibition rate (TGI) was 96.83%, which was significantly different from that of the control group (P < 0.01).
[0296] The anti-tumor activity of the combination drug group was significantly better than that of each single drug group, and showed significant synergistic effect.
[0297] Example 9 Evaluation of the anti-tumor effect of the combination of fusion protein and anti-CTLA-4 antibody using the MC38 subcutaneous implant model
[0298] The synergistic effect of the combination of the CD80 fusion protein of the present application and the anti-m-CTLA-4 antibody was studied. The anti-m-CTLA-4 antibody used in the study was purchased from Bioxcell, catalog number BP0164. Mouse colorectal cancer cells MC38 were inoculated subcutaneously in the right anterior flank of female C57BL / 6 mice. On the 7th day after inoculation, the average tumor volume was approximately 78 mm. 3 Tumor-bearing mice were randomly divided into four groups using the randomized block method: Group 1: PBS group (hereinafter referred to as Group 1), Group 2: CD80M28 (0.5 mg / kg) group (hereinafter referred to as Group 2), Group 3: CTLA-4 (4 mg / kg) group (hereinafter referred to as Group 3), and Group 4: CTLA-4 (5 mg / kg) + CD80M28 (0.4 mg / kg) group (hereinafter referred to as Group 4), with six mice in each group. CD80M28 was administered intravenously once, and the CTLA-4 antibody was administered intraperitoneally twice a week for a total of three doses.
[0299] On Day 17, subcutaneous tumors disappeared in both the Anti-mCTLA-4 4 mg / kg (G3) and CD80M28 + Anti-mCTLA-4 (G4) combination groups. By Day 24, subcutaneous tumors disappeared in two animals in the Anti-mCTLA-4 4 mg / kg (G3) group, for a tumor elimination rate of 33.3%. Subcutaneous tumors disappeared in five animals in the CD80M28 + Anti-mCTLA-4 (G4) combination group, for a tumor elimination rate of 83.3%, demonstrating superior activity to either single-agent group. See Figure 13 for the results.
[0300] Example 10 CD80 fusion protein induces cytokine release
[0301] The ability of CD80 fusion protein to induce PBMC to release cytokines was evaluated by ELISA using CD3 antibody hOKT3 and CD28 antibody TGN1412 as controls.
[0302] Different concentrations of CD80 fusion protein, CD3 antibody hOKT3 (Human CD3 (humanized OKT3) Antibody-Human IgG4 (GMP-grade, Sino Biological), CD28 antibody TGN1412 (self-produced) and IgG1-Fc protein (Human IgG1 Fc Protein, Tag Free, ACROBiosystems) were added to a 96-well cell culture plate and air-dried overnight at room temperature. After washing twice with physiological saline, 1×10 5PBMC cells from healthy donors (Schbio Biotech) were incubated in a 37°C incubator for 24 hours, and the supernatant was collected. The levels of TNF-α and IL-6 in the supernatant were detected using TNF-α ELISA kit (HUMAN TNF-α ELISA KIT, ExCell Bio) and IL-6 ELISA kit (Human IL-6 Precoated ELISA Kit, DAKEWE), respectively, to analyze the ability of CD80 fusion protein to induce PBMC to release cytokines.
[0303] The results are shown in Figures 14A-14B, which show that CD80-WT and CD80M28 do not stimulate cytokine release and therefore have good safety.
[0304] Example 11 Analysis of Charge Heterogeneity of CD80 Fusion Protein
[0305] Taking CD80M26 and CD80M28 as examples, the charge heterogeneity of CD80 variant fusion proteins was analyzed. The capillary was rinsed at room temperature, and the mixed standard sample solution and the detection sample solution were prepared. The preparation method of CD80M28 solution was: 1% MC 50uL, 8.6mM urea 50Ul, 200mM IDA, 10ul, 500mM arginine 7uL, 1mg / mL CD80M28, 25uL, ampholytes 3-10, 1.6uL, ampholytes 5-8, 6.4uL. CD80-WT and CD80M26 solutions were prepared as follows: 50 μL of 1% MC, 50 μL of 8.6 mM urea, 10 μL of 200 mM IDA, 7 μL of 500 mM arginine, 25 μL of 1 mg / mL CD80-WT, 1.2 μL of ampholytes 3-10, and 10.8 μL of ampholytes 5-8. Electrophoresis was performed using an injection pressure of 2 bar and an injection time of 100 seconds. Chromatograms were collected to separate charge heterogeneity. Acid-base variants were quantified using area normalization.
[0306] The results are shown in Figure 15, showing that the charge heterogeneity of CD80M26 and CD80M28 is significantly lower than that of CD80-WT. Proteins with charge heterogeneity have more uniform quality control and better druggability.
[0307] Example 12 HPLC-FLD was used to detect and analyze the sialic acid ratio of CD80M28 samples from different cell clones
[0308] Using CD80M28 as an example, the effect of sialic acid ratio was examined. Sialic acid content was determined using HPLC-FLD. The protein sample was diluted with PBS five times, then the protein concentration was determined. The protein was then diluted to 1 mg / mL. 4 M acetic acid was added to the sample at a 1:1 ratio, mixed, and incubated at 80°C for 2 hours. To this system, 50 μL of DMB solution was added, and the mixture was incubated at 50°C for 2.5 hours. Standard curves were drawn using different concentrations of two sialic acid quantitative standards commonly found in glycoproteins, Neu5Ac(NA) / Neu5Gc(NG), for quantitative analysis of Neu5Ac(NA) / Neu5Gc(NG).
[0309] Example 13 Evaluation of the anti-tumor effect of CD80M28 with different sialic acid modification degrees using the CT26 subcutaneous implantation model
[0310] Mouse colorectal cancer cells CT26 were inoculated subcutaneously in the right anterior flank of female BABL / C mice. A total of 20 mice were inoculated. When the tumor grew to 80 mm 3 The mice were divided into 7 groups with 6 mice in each group. The drug-treated groups were G1 vehicle control (PBS), G2 CD80M28-15, G3 CD80M28-1, G4 CD80M28-12, G5 CD80M28-99, G6 CD80M28-5, and G7 CD80-WT. The drugs were administered once every three days, for a total of 3 times.
[0311] The average tumor volume of the vehicle control group at the end of the experiment was 2906.96 mm 3 The average tumor volume of the CD80M28-15 treatment group at the end of the experiment was 1979.69 mm 3 The relative tumor inhibition rate (TGI) was 31.90%; the average tumor volume of the CD80M28-1 treatment group at the end of the experiment was 2536.42 mm 3 The relative tumor inhibition rate (TGI) was 12.75%; the average tumor volume of the CD80M28-12 treatment group at the end of the experiment was 1683.28 mm 3 The relative tumor inhibition rate (TGI) was 42.09%; the average tumor volume of the CD80M28-9 treatment group at the end of the experiment was 1612.37 mm 3 The relative tumor inhibition rate (TGI) was 44.53%; the average tumor volume of the CD80M28-5 treatment group at the end of the experiment was 1940.70 mm 3 The relative tumor inhibition rate (TGI) was 33.24%; the average tumor volume of the CD80-WT treatment group at the end of the experiment was 2805.13 mm 3, the relative tumor inhibition rate (TGI) was 3.50%.
[0312] The results are shown in Figure 16 , demonstrating that CD80M28 proteins with varying sialic acid contents exhibited superior tumor suppression effects compared to wild-type CD80-WT. When the sialic acid content was greater than 0.76, the CD80 fusion protein exhibited a more pronounced tumor suppression rate. In particular, when the sialic acid content was greater than 1, the CD80 fusion protein exhibited a significantly higher tumor suppression rate. This suggests that increasing the sialic acid content can enhance the tumor suppression effect of the CD80 fusion protein.
[0313] Example 14 Pharmacokinetic Animal Experiment
[0314] After a single intravenous infusion of CD80-WT-G1 (CD80-WT) and CD80M28 stock solutions into Sprague Dawley rats, the concentrations of the test substances in serum were detected and the pharmacokinetic characteristics of the two test substances were compared to provide data support for subsequent experiments.
[0315] Analytical methods:
[0316] Quantitative range: 50.0~3200ng / mL
[0317] Experimental design: Table 1
[0318] Note: The drug is administered by intravenous infusion for 4 minutes.
[0319] Sample collection:
[0320] A total of 14 time points and 224 samples were collected, including 0 min before administration, 5 min, 30 min, 2 h, 4 h, 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 240 h, and 336 h after administration.
[0321] Experimental results: Table 2
[0322] Mean pharmacokinetic parameters of each group after a single intravenous infusion of CD80-WT-G1 (CD80-WT) and CD80M28 stock solutions in Sprague Dawley rats (Mean±SD, n=8) Note: T max The mean was expressed as median or median and range (minimum, maximum). SPSS software was used for independent sample t-test analysis. P>0.05: no statistical difference between the groups; P<0.05: there was a statistical difference between the groups.
[0323] After a single intravenous infusion of 2 mg / kg CD80-WT-G1 and 2 mg / kg CD80M28 stock solution in Sprague Dawley rats, the C max , AUC (0-t) and AUC inf The results showed that the difference between the CD80-WT-G1 and CD80M28 dose groups was 1.44, 26.3 and 23.8 times, CL was 0.0396 times, and MRT was 2.60 times. el , t 1 / 2 and T max There was no statistical difference in the other parameters C max , AUC (0-t) , AUC inf , AUC extr 、V d , CL, and MRT showed significant statistical differences. The mean plasma concentration-time curves for Sprague Dawley rats following a single intravenous infusion of CD80-WT-G1 and CD80M28 stock solutions are shown in Figure 17. These results suggest that CD80M28 has a higher exposure, slower clearance, and a longer sustained exposure in vivo in rats.
Claims
1. A CD80 protein variant comprising a functionally active fragment of a CD80 protein or a variant thereof, wherein the variant has a mutation in one or more amino acid positions compared to the corresponding functionally active fragment of wild-type CD80, and the variant has one or more of the following characteristics: a) Binding to PD-L1; b) binds to CTLA-4; c) binds to CD28; d) activation of T lymphocyte activity; and e) inhibiting the growth and / or proliferation of tumors or tumor cells.
2. The CD80 protein variant according to claim 1, wherein the PD-L1 is human PD-L1, wherein the CTLA-4 is human CTLA-4, and wherein the CD28 is human CD28.
3. The CD80 protein variant according to claim 1 or 2, wherein the functionally active fragment of the CD80 protein comprises the extracellular domain (ECD) of the CD80 protein or a fragment thereof. 4 . The CD80 protein variant according to claim 3 , wherein the fragment of the extracellular domain of the CD80 protein comprises the IgV domain of the CD80 protein.
5. The CD80 protein variant according to any one of claims 1 to 4, comprising an amino acid mutation at one or more amino acid residues selected from the group consisting of N55, N64, N152, N173, N177, N192, and N198, compared to the corresponding wild-type CD80 protein extracellular domain or a fragment thereof.
6. The CD80 protein variant according to any one of claims 1 to 5, comprising a mutation at any one of the following groups of amino acid positions: 1)N64; 2) N55 and N64; 3) N55, N64 and N152; 4) N55, N64 and N192; 5) N55, N64 and N198; 6) N55, N64, N152 and N198; 7) N55, N64, N152 and N192; 8) N55, N64, N152, N173, N177 and N198; 9) N55, N64, N152, N173, and N198; and 10) N55, N64, N152, N177 and N198.
7. The CD80 protein variant according to any one of claims 1 to 6, comprising one or more amino acid mutations selected from the group consisting of N55A / Q, N64A, N152A, N173Q, N177A, N192A, and N198A / Q.
8. The CD80 protein variant according to any one of claims 1 to 7, comprising any one group of amino acid mutations selected from the following group: 1)N64A; 2) N55A and N64A; 3) N55A, N64A, and N152A; 4) N55A, N64A, and N192A; 5) N55A, N64A, and N198A; 6) N55A, N64A, N152A, and N198A; 7) N55A, N64A, N152A, and N192A; 8) N55Q, N64A, N152A and N198Q; 9) N55Q, N64A, N152A, N173Q, N177A, and N198Q; 10) N55Q, N64A, N152A, N173Q, and N198Q; and 11) N55Q, N64A, N152A, N177A and N198Q.
9. The CD80 protein variant according to any one of claims 1 to 8, comprising at least one first type of amino acid mutation, wherein the first type of amino acid mutation can maintain or enhance the stability of the CD80 protein variant.
10. The CD80 protein variant according to claim 9, comprising a first class amino acid mutation at one or more of the following amino acid positions: N55, N64, N152, N192 and N198.
11. The CD80 protein variant according to any one of claims 9-10, comprising a first type of amino acid mutation at any one of the amino acid positions selected from the group consisting of: 1)N64; 2) N55 and N64; 3) N55, N64 and N152; 4) N55, N64 and N192; 5) N55, N64 and N198; 6) N55, N64, N152, and N198; and 7)N55, N64, N152 and N192.
12. The CD80 protein variant according to any one of claims 9 to 11, comprising one or more of the following first class amino acid mutations: N55A / Q, N64A, N152A, N192A, and N198A / Q.
13. The protein variant according to any one of claims 9 to 12, comprising any group of first-class amino acid mutations selected from the group consisting of: 1)N64A; 2) N55A and N64A; 3) N55A, N64A, and N152A; 4) N55A, N64A, and N192A; 5) N55A, N64A, and N198A; 6) N55A, N64A, N152A, and N198A; 7) N55A, N64A, N152A, and N192A; and 8)N55Q, N64A, N152A and N198Q. 14 . The CD80 protein variant according to claim 1 , comprising at least one second type of amino acid mutation, wherein the second type of amino acid mutation is capable of maintaining the binding activity of the CD80 protein variant.
15. The CD80 protein variant according to claim 14, comprising a second type of amino acid mutation at one or more of the following positions: N152; N192 and N198.
16. The CD80 protein variant according to any one of claims 14-15, comprising one or more of the following second-class amino acid mutations: N152A; N192A and N198A / Q.
17. The CD80 protein variant according to any one of claims 14 to 16, comprising a second type of amino acid mutation at position N55 and / or N64.
18. The CD80 protein variant according to any one of claims 14 to 17, comprising a second type of amino acid mutation of N55A / Q and / or N64A.
19. The CD80 protein variant according to any one of claims 1 to 18, comprising at least one third type of amino acid mutation, wherein the amino acid mutation is capable of maintaining the affinity of the CD80 protein variant.
20. The CD80 protein variant according to claim 19, comprising a third type of amino acid mutation at one or more of the following positions: N55, N64, N152 and N198.
21. The CD80 protein variant according to any one of claims 19-20, comprising one or more of the following third class amino acid mutations: N55A / Q, N64A, N152A, and N198A.
22. The CD80 protein variant according to any one of claims 19 to 21, comprising a third type of amino acid mutation at position N192.
23. The CD80 protein variant according to any one of claims 19 to 22, comprising a third amino acid mutation of N192A.
24. The CD80 protein variant according to any one of claims 1 to 23, comprising at least one fourth amino acid mutation, wherein the mutation is capable of enhancing the binding of the CD80 protein variant to CD28 and / or PD-L1. The CD80 protein variant according to claim 24 , comprising a fourth type of amino acid mutation at position N173 and / or N177.
26. The CD80 protein variant according to any one of claims 24-25, comprising the fourth type of amino acid mutation of N173Q and / or N177A.
27. The CD80 protein variant according to any one of claims 1-26, wherein the numbering of the amino acid positions is determined with reference to the position numbering of the amino acids in SEQ ID NO:
1.
28. The CD80 protein variant according to any one of claims 1-27, comprising the amino acid sequence shown in any one of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23 and SEQ ID NO:
24.
29. The CD80 protein variant according to any one of claims 1 to 28, wherein the sialic acid content thereof is greater than or equal to about 0.
7.
30. A fusion protein comprising the CD80 protein variant according to any one of claims 1-29. The fusion protein of claim 30 , further comprising an immunoglobulin Fc region or a variant thereof. The fusion protein of claim 31 , wherein the CD80 protein variant and the immunoglobulin Fc region are directly or indirectly linked.
33. The fusion protein of any one of claims 31-32, wherein the immunoglobulin Fc region comprises the Fc region of IgG. The fusion protein of claim 33 , wherein the IgG is selected from the group consisting of IgG1 and IgG4.
35. The fusion protein according to any one of claims 31 to 34, wherein the CD80 protein variant is located at the N-terminus or C-terminus of the immunoglobulin Fc region.
36. The fusion protein of any one of claims 31-35, wherein the immunoglobulin Fc region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 25 and SEQ ID NO:
26.
37. The fusion protein according to any one of claims 30 to 36, comprising the amino acid sequence shown in any one of SEQ ID NOs: 27 to 37.
38. A polypeptide comprising the CD80 protein variant according to any one of claims 1 to 29, or the fusion protein according to any one of claims 30 to 37.
39. An isolated nucleic acid molecule or molecules encoding the CD80 protein variant of any one of claims 1-29, the fusion protein of any one of claims 30-37, or the polypeptide of claim 38.
40. A vector comprising the nucleic acid molecule of claim 39.
41. A host cell comprising the nucleic acid molecule of claim 39 or the vector of claim 40.
42. A method for preparing the CD80 protein variant of any one of claims 1-29 or the fusion protein of any one of claims 30-37, the method comprising culturing the cell of claim 41 under conditions allowing expression of the fusion protein.
43. A pharmaceutical composition comprising the CD80 protein variant of any one of claims 1-29, the fusion protein of any one of claims 30-37, the polypeptide of claim 38, the nucleic acid molecule of claim 39, the vector of claim 40 and / or the host cell of claim 41, and optionally a pharmaceutically acceptable carrier.
44. A pharmaceutical combination comprising the CD80 protein variant according to any one of claims 1 to 19, the fusion protein according to any one of claims 30 to 37, or the polypeptide according to claim 38, and an immune checkpoint inhibitor.
45. The pharmaceutical combination of claim 44, wherein the immune checkpoints comprise PD-1, PD-L1, GITR and / or CTLA-4.
46. The pharmaceutical combination according to any one of claims 44-45, wherein the immune checkpoint inhibitor comprises one or more selected from the group consisting of a PD-1 antibody, a PD-L1 antibody, a CTLA-4 antibody, and a GITR antibody.
47. A method of modulating an immune response in a subject, the method comprising administering the CD80 protein variant of any one of claims 1-29, the fusion protein of any one of claims 30-37, or the polypeptide of claim 38.
48. The method of claim 41, wherein the method of modulating an immune response in a subject comprises increasing an immune response.
49. The method of any one of claims 47-48, wherein the CD80 protein variant exhibits increased binding affinity to PD-L1 compared to wild-type CD80 protein or a fragment thereof.
50. The method of any one of claims 47-49, wherein the CD80 protein variant exhibits increased binding affinity for CD28 compared to wild-type CD80 protein or fragment thereof.
51. The method according to any one of claims 47-50, wherein the CD80 protein variant exhibits enhanced activity in activating T lymphocytes compared to the wild-type CD80 protein or fragment thereof.
52. Use of the CD80 protein variant of any one of claims 1-29, the fusion protein of any one of claims 30-37, the polypeptide of claim 38, the nucleic acid molecule of claim 39, the vector of claim 40, the host cell of claim 41, the pharmaceutical composition of claim 43, or the pharmaceutical combination of any one of claims 44-46 in the preparation of a medicament for preventing and / or treating a disease and / or condition.
53. The use according to claim 52, wherein the disease and / or condition comprises a tumor.
54. The use according to claim 53, wherein the tumor comprises a solid tumor and / or a hematological tumor.
55. The use according to any one of claims 53-54, wherein the tumor comprises a tumor responsive to the proliferation of central memory T cells.
56. The use according to any one of claims 53 to 55, wherein the tumor is selected from one or more of the following groups: malignant melanoma, breast cancer, gastric cancer, renal cancer, non-small cell lung cancer, colon cancer, rectal cancer, head and neck squamous cell carcinoma, liver cancer, kidney cancer, mesothelioma, bladder cancer, pancreatic cancer, ovarian cancer, endometrial cancer and lymphoma.
57. A method for preventing and / or treating a disease and / or condition, the method comprising administering to a subject in need thereof the CD80 protein variant of any one of claims 1-29, the fusion protein of any one of claims 30-37, the polypeptide of claim 38, the nucleic acid molecule of claim 39, the vector of claim 40, the host cell of claim 41, the pharmaceutical composition of claim 43, or the pharmaceutical combination of any one of claims 44-46.
58. The method of claim 57, wherein the disease and / or condition comprises a tumor.
59. The method of claim 58, wherein the tumor comprises a solid tumor and / or a hematological tumor.
60. The method of any one of claims 58-59, wherein the tumor comprises a tumor responsive to proliferation of central memory T cells.
61. The method of any one of claims 58-60, wherein the tumor is selected from one or more of the following groups: malignant melanoma, breast cancer, gastric cancer, renal cancer, non-small cell lung cancer, colon cancer, rectal cancer, head and neck squamous cell carcinoma, liver cancer, kidney cancer, mesothelioma bladder cancer, pancreatic cancer, ovarian cancer, endometrial cancer, and lymphoma.
62. The CD80 protein variant of any one of claims 1-29, the fusion protein of any one of claims 30-37, the polypeptide of claim 38, the nucleic acid molecule of claim 39, the vector of claim 40, the host cell of claim 41, the pharmaceutical composition of claim 43, or the pharmaceutical combination of any one of claims 44-46, for use in preventing and / or treating a disease and / or condition.
63. The CD80 protein variant, fusion protein, nucleic acid molecule, vector, host cell, pharmaceutical composition or pharmaceutical combination according to claim 62, wherein the disease and / or disorder comprises a tumor.
64. The CD80 protein variant, fusion protein, nucleic acid molecule, vector, host cell, pharmaceutical composition or pharmaceutical combination according to claim 63, wherein the tumor comprises a solid tumor and / or a hematological tumor.
65. The CD80 protein variant, fusion protein, nucleic acid molecule, vector, host cell, pharmaceutical composition or pharmaceutical combination of any one of claims 63-64, wherein the tumor comprises a tumor responsive to the proliferation of central memory T cells.
66. The CD80 protein variant, fusion protein, nucleic acid molecule, vector, host cell, pharmaceutical composition or pharmaceutical combination according to any one of claims 63 to 65, wherein the tumor is selected from one or more of the following groups: malignant melanoma, breast cancer, gastric cancer, renal cancer, non-small cell lung cancer, colon cancer, rectal cancer, head and neck squamous cell carcinoma, liver cancer, kidney cancer, mesothelioma, bladder cancer, pancreatic cancer, ovarian cancer, endometrial cancer and lymphoma.
67. A method for detecting the frequency and / or proliferation of central memory T cells in a subject, the method comprising administering the CD80 protein variant of any one of claims 1-29, the fusion protein of any one of claims 30-37, or the polypeptide of claim 38.
68. The method of claim 67, wherein the central memory T cells are CD95+ and CD28+ cells.
69. The method of claim 67, wherein the central memory T cells are CD4+ central memory T cells and / or CD8+ central memory T cells.
70. The CD80 protein variant of any one of claims 1-29, the fusion protein of any one of claims 30-37, the polypeptide of claim 38, the nucleic acid molecule of claim 39, the vector of claim 40, the host cell of claim 41, the pharmaceutical composition of claim 43, or the pharmaceutical combination of any one of claims 44-46, for enhancing the proliferation or frequency of central memory T cells.
